Terms: = Head and neck cancer AND REL, I-Rel, 5966, ENSG00000162924, C-Rel AND Treatment
5 results:
1. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the head and neck.
Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
[TBL] [Abstract] [Full Text] [Related]
2. Quality-of-life-adjusted survival analysis of concurrent chemo radiotherapy for locally advanced (nonmetastatic) nasopharyngeal cancer.
Gao F; Wee J; Wong HB; Machin D
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):454-60. PubMed ID: 20092962
[TBL] [Abstract] [Full Text] [Related]
3. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of uncertainty-based stopping criteria for monte carlo calculations of intensity-modulated radiotherapy and arc therapy patient dose distributions.
Vanderstraeten B; Olteanu AM; Reynaert N; Leal A; De Neve W; Thierens H
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):628-37. PubMed ID: 17869677
[TBL] [Abstract] [Full Text] [Related]
5. Molecular and biochemical reprogramming of oncogenesis through the activity of prooxidants and antioxidants.
Schwartz JL; Antoniades DZ; Zhao S
Ann N Y Acad Sci; 1993 May; 686():262-78; discussion 278-9. PubMed ID: 8512252
[TBL] [Abstract] [Full Text] [Related]
